![Loading...](https://link.springer.com/static/c4a417b97a76cc2980e3c25e2271af3129e08bbe/images/pdf-preview/spacer.gif)
-
Article
Dating of anatase-forming diagenetic reactions in Rotliegend sandstones of the North German Basin
Diagenetic conditions controlling authigenic formation of anatase and in situ LA-ICP-MS U–Pb isotope dating of this phase are studied in Upper Rotliegend II sandstones from two wells in NW-Germany. Anatase gre...
-
Article
Pneumologen-Barometer 2017
Erstmalig wurde mittels Online-Befragung eine Selbsteinschätzung von ambulant in Praxen und stationär in Kliniken tätigen Pneumologen zu Therapieoptionen und ihrer Umsetzbarkeit, zur Verordnungssituation, dem ...
-
Article
Open AccessTreatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study
The single-arm, phase 2 ENESTfreedom trial assessed the potential for treatment-free remission (TFR; i.e., the ability to maintain a molecular response after stop** therapy) following frontline nilotinib tre...
-
Article
Positionspapier zum Telemonitoring bei schlafbezogenen Atmungsstörungen
Der Einsatz des Telemonitorings bei schlafbezogenen Atmungsstörungen (SBAS) kann zukünftig die Betreuung der Patienten wesentlich unterstützen. Ziel ist es dabei, den Ärzten zu ermöglichen, Therapieprobleme ze...
-
Article
Treatment and outcome of 2904 CML patients from the EUTOS population-based registry
The European Treatment and Outcome Study (EUTOS) population-based registry includes data of all adult patients newly diagnosed with Philadelphia chromosome-positive and/or BCR-ABL1+ chronic myeloid leukemia (C...
-
Article
Open AccessLong-term outcome of patients with newly diagnosed chronic myeloid leukemia: a randomized comparison of stem cell transplantation with drug treatment
Tyrosine kinase inhibitors represent today’s treatment of choice in chronic myeloid leukemia (CML). Allogeneic hematopoietic stem cell transplantation (HSCT) is regarded as salvage therapy. This prospective ra...
-
Article
Open AccessFrontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the European ENEST1st study
The Evaluating Nilotinib Efficacy and Safety in Clinical Trials as First-Line Treatment (ENEST1st) study included 1089 patients with newly diagnosed chronic myeloid leukemia in chronic phase. The rate of deep ...
-
Article
The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries
This population-based registry was designed to provide robust and updated information on the characteristics and the epidemiology of chronic myeloid leukemia (CML). All cases of newly diagnosed Philadelphia po...
-
Article
Aus der Versorgungsforschung des Bundesverbandes der Pneumologen – WINPNEU
Patienten mit Asthma und COPD stellen den wesentlichen Anteil einer pneumologischen Praxis dar und stehen im Mittelpunkt des alltäglichen Versorgungsauftrags der Pneumologen. Die vorliegende Untersuchung hat d...
-
Article
Open AccessLeukemia and risk of recurrent Escherichia coli bacteremia: genoty** implicates E. coli translocation from the colon to the bloodstream
In patients with leukemia, the portal(s) and reasons for the persistence of an Escherichia coli recurrent bacteremia remain unclear. Adult Hematology Clinic (AHC) databases at the State Clinical Hospital in Gdańs...
-
Article
The EUTOS prognostic score: review and validation in 1288 patients with CML treated frontline with imatinib
The introduction of tyrosine kinase inhibitors (TKI) in the treatment of Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) has revolutionized the outcome, but the prognosis of the disease i...
-
Article
Hydrothermal gold mineralization at the Hira Buddini gold mine, India: constraints on fluid evolution and fluid sources from boron isotopic compositions of tourmaline
We determined the boron isotope and chemical compositions of tourmaline from the Hira Buddini gold deposit within the Archean Hutti-Maski greenstone belt in southern India to investigate the evolution of the h...
-
Article
Prevention of hepatitis B virus transmission from an infected stem cell donor
-
Article
Allogeneic bone marrow transplantation for hypereosinophilic syndrome: long-term follow-up with eradication of FIP1L1-PDGFRA fusion transcript
-
Article
A multicenter, open, noncomparative, phase II study of the combination of cladribine (2-chlorodeoxyadenosine), cytarabine, granulocyte colony-stimulating factor and mitoxantrone as induction therapy in refractory acute myeloid leukemia: a report of the Polish Adult Leukemia Group
Purine nucleoside analogues, cladribine (2-chlorodeoxyadenosine, 2-CdA) and fludarabine (FAMP) are active agents in acute myeloid leukemias (AMLs). Synergistic interaction between FAMP or 2-CdA with cytarabine...
-
Article
Imatinib therapy prior to myeloablative allogeneic stem cell transplantation
It is unknown whether imatinib prior to myeloablative haematopoietic stem cell transplantation (HSCT) increases transplant-related toxicity. Among the side effects induced by imatinib, myelosuppression and liv...
-
Article
Early complete donor hematopoietic chimerism in peripheral blood indicates the risk of extensive graft-versus-host disease
Achievement of complete donor hematopoietic chimerism (CC) is the goal of allogeneic stem cell transplantation (allo-SCT). Persistence of recipient hematopoiesis augments the risk of relapse, which is one of t...
-
Article
Open AccessAn evaluation of factors predicting long-term response to thalidomide in 234 patients with relapsed or resistant multiple myeloma
The aim of this study was to assess the prognostic value of pretreatment clinical and laboratory parameters in refractory or relapsed multiple myeloma (MM) patients who have a long-term response to thalidomide...
-
Article
Treatment for primary refractory Hodgkin's disease: a comparison of high-dose chemotherapy followed by ASCT with conventional therapy
Our previously published study showed promising results of autologous stem cell transplantation (ASCT) in patients with primary resistant Hodgkin's disease (HD). Probabilities of overall survival (OS) and prog...
-
Article
Addition of cladribine to daunorubicin and cytarabine increases complete remission rate after a single course of induction treatment in acute myeloid leukemia. Multicenter, phase III study
To assess the efficacy of an original DAC-7 regimen: daunorubicine (DNR) 60 mg/m2/day, days 1–3; cytarabine (AraC) 200 mg/m2/day, days 1–7; cladribine (2-CdA) 5 mg/m2/day, days 1–5, 400 untreated adult acute myel...